Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Multiple Sclerosis Relapses Following Cessation of Fingolimod

CB. Malpas, I. Roos, S. Sharmin, K. Buzzard, O. Skibina, H. Butzkueven, L. Kappos, F. Patti, R. Alroughani, D. Horakova, EK. Havrdova, G. Izquierdo, S. Eichau, S. Hodgkinson, P. Grammond, J. Lechner-Scott, T. Kalincik, MSBase Study Group

. 2022 ; 42 (4) : 355-364. [pub] 20220318

Language English Country New Zealand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22018924

Grant support
1129189 National Health and Medical Research Council
1140766 National Health and Medical Research Council
1080518 National Health and Medical Research Council

E-resources Online Full text

NLK ProQuest Central from 2008-06-01 to 1 year ago
Health & Medicine (ProQuest) from 2008-06-01 to 1 year ago

Links

PubMed 35303292
DOI 10.1007/s40261-022-01129-7
Knihovny.cz E-resources

BACKGROUND: There is growing interest in the issue of disease reactivation in multiple sclerosis following fingolimod cessation. Relatively little is known about modifiers of the risk of post-cessation relapse, including the delay to commencement of new therapy and prior disease activity. OBJECTIVE: We aimed to determine the rate of relapse following cessation of fingolimod and to identify predictors of relapse following cessation. METHODS: Data were extracted from the MSBase registry in March 2019. Inclusion criteria were (a) clinically definite relapsing multiple sclerosis, (b) treatment with fingolimod for ≥ 12 months, (c) follow-up after cessation for ≥ 12 months, and (d) at least one Expanded Disability Status Scale score recorded in the 12 months before cessation. RESULTS: A total of 685 patients were identified who met criteria. The mean annualised relapse rate was 1.71 (95% CI 1.59, 1.85) in the year prior to fingolimod, 0.50 (95% CI 0.44, 0.55) on fingolimod and 0.43 (95% CI 0.38, 0.49) after fingolimod. Of these, 218 (32%) patients experienced a relapse in the first 12 months. Predictors of a higher relapse rate in the first year were: younger age at fingolimod cessation, higher relapse rate in the year prior to cessation, delaying commencement of new therapy and switching to low-efficacy therapy. CONCLUSIONS: Disease reactivation following fingolimod cessation is more common in younger patients, those with greater disease activity prior to cessation and in those who switch to a low-efficacy therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018924
003      
CZ-PrNML
005      
20220804135205.0
007      
ta
008      
220720s2022 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40261-022-01129-7 $2 doi
035    __
$a (PubMed)35303292
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Malpas, Charles B $u Department of Medicine, CORe, University of Melbourne, Melbourne, VIC, Australia $u Department of Neurology, Royal Melbourne Hospital, Melbourne MS Centre, Melbourne, VIC, Australia
245    10
$a Multiple Sclerosis Relapses Following Cessation of Fingolimod / $c CB. Malpas, I. Roos, S. Sharmin, K. Buzzard, O. Skibina, H. Butzkueven, L. Kappos, F. Patti, R. Alroughani, D. Horakova, EK. Havrdova, G. Izquierdo, S. Eichau, S. Hodgkinson, P. Grammond, J. Lechner-Scott, T. Kalincik, MSBase Study Group
520    9_
$a BACKGROUND: There is growing interest in the issue of disease reactivation in multiple sclerosis following fingolimod cessation. Relatively little is known about modifiers of the risk of post-cessation relapse, including the delay to commencement of new therapy and prior disease activity. OBJECTIVE: We aimed to determine the rate of relapse following cessation of fingolimod and to identify predictors of relapse following cessation. METHODS: Data were extracted from the MSBase registry in March 2019. Inclusion criteria were (a) clinically definite relapsing multiple sclerosis, (b) treatment with fingolimod for ≥ 12 months, (c) follow-up after cessation for ≥ 12 months, and (d) at least one Expanded Disability Status Scale score recorded in the 12 months before cessation. RESULTS: A total of 685 patients were identified who met criteria. The mean annualised relapse rate was 1.71 (95% CI 1.59, 1.85) in the year prior to fingolimod, 0.50 (95% CI 0.44, 0.55) on fingolimod and 0.43 (95% CI 0.38, 0.49) after fingolimod. Of these, 218 (32%) patients experienced a relapse in the first 12 months. Predictors of a higher relapse rate in the first year were: younger age at fingolimod cessation, higher relapse rate in the year prior to cessation, delaying commencement of new therapy and switching to low-efficacy therapy. CONCLUSIONS: Disease reactivation following fingolimod cessation is more common in younger patients, those with greater disease activity prior to cessation and in those who switch to a low-efficacy therapy.
650    _2
$a fingolimod hydrochlorid $x škodlivé účinky $7 D000068876
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x škodlivé účinky $7 D007166
650    12
$a roztroušená skleróza $7 D009103
650    12
$a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
650    _2
$a recidiva $7 D012008
655    _2
$a časopisecké články $7 D016428
700    1_
$a Roos, Izanne $u Department of Medicine, CORe, University of Melbourne, Melbourne, VIC, Australia $u Department of Neurology, Royal Melbourne Hospital, Melbourne MS Centre, Melbourne, VIC, Australia
700    1_
$a Sharmin, Sifat $u Department of Medicine, CORe, University of Melbourne, Melbourne, VIC, Australia $u Department of Neurology, Royal Melbourne Hospital, Melbourne MS Centre, Melbourne, VIC, Australia
700    1_
$a Buzzard, Katherine $u Box Hill Hospital, Melbourne, VIC, Australia $u Monash University, Melbourne, VIC, Australia $u Royal Melbourne Hospital, Melbourne MS Centre, Melbourne, VIC, Australia
700    1_
$a Skibina, Olga $u Box Hill Hospital, Melbourne, VIC, Australia $u Monash University, Melbourne, VIC, Australia $u The Alfred Hospital, Melbourne, VIC, Australia
700    1_
$a Butzkueven, Helmut $u Central Clinical School, Monash University, Melbourne, VIC, Australia $u Department of Neurology, The Alfred Hospital, Melbourne, VIC, Australia $u Department of Neurology, Box Hill Hospital, Monash University, Melbourne, VIC, Australia
700    1_
$a Kappos, Ludwig $u Departments of Medicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Basel, Switzerland
700    1_
$a Patti, Francesco $u GF Ingrassia Department, University of Catania, Catania, Italy $u Policlinico G Rodolico, Catania, Italy
700    1_
$a Alroughani, Raed $u Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait
700    1_
$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Havrdova, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Izquierdo, Guillermo $u Hospital Universitario Virgen Macarena, Sevilla, Spain
700    1_
$a Eichau, Sara $u Hospital Universitario Virgen Macarena, Sevilla, Spain
700    1_
$a Hodgkinson, Suzanne $u Liverpool Hospital, Sydney, NSW, Australia
700    1_
$a Grammond, Pierre $u CISSS ChaudiËre-Appalache, Levis, QC, Canada
700    1_
$a Lechner-Scott, Jeannette $u School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia $u Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia
700    1_
$a Kalincik, Tomas $u Department of Medicine, CORe, University of Melbourne, Melbourne, VIC, Australia. tomas.kalincik@unimelb.edu.au $u Department of Neurology, Royal Melbourne Hospital, Melbourne MS Centre, Melbourne, VIC, Australia. tomas.kalincik@unimelb.edu.au $u L4 Centre, Melbourne Brain Centre at Royal Melbourne Hospital, Grattan Street, Parkville, VIC, 3050, Australia. tomas.kalincik@unimelb.edu.au $1 https://orcid.org/0000000337781376 $7 xx0121848
710    2_
$a MSBase Study Group
773    0_
$w MED00001123 $t Clinical drug investigation $x 1179-1918 $g Roč. 42, č. 4 (2022), s. 355-364
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35303292 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135159 $b ABA008
999    __
$a ok $b bmc $g 1822493 $s 1170167
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 42 $c 4 $d 355-364 $e 20220318 $i 1179-1918 $m Clinical drug investigation $n Clin. drug invest. $x MED00001123
GRA    __
$a 1129189 $p National Health and Medical Research Council
GRA    __
$a 1140766 $p National Health and Medical Research Council
GRA    __
$a 1080518 $p National Health and Medical Research Council
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options